Multimode, Cooperative Mechanism of Action of Allosteric HIV-1 Integrase Inhibitors*

Background: 2-(Quinolin-3-yl)-acetic-acid derivatives target HIV-1 integrase and inhibit viral replication. Results: The compounds are allosteric integrase inhibitors (ALLINIs) that block integrase interactions with viral DNA and its cellular cofactor LEDGF and cooperatively inhibit HIV-1 replication. Conclusion: ALLINIs block multiple steps of HIV-1 integration. Significance: These new properties of ALLINIs will facilitate their further development as potent antiretroviral compounds. The multifunctional HIV-1 enzyme integrase interacts with viral DNA and its key cellular cofactor LEDGF to effectively integrate the reverse transcript into a host cell chromosome. These interactions are crucial for HIV-1 replication and present attractive targets for antiviral therapy. Recently, 2-(quinolin-3-yl) acetic acid derivatives were reported to selectively inhibit the integrase-LEDGF interaction in vitro and impair HIV-1 replication in infected cells. Here, we show that this class of compounds impairs both integrase-LEDGF binding and LEDGF-independent integrase catalytic activities with similar IC50 values, defining them as bona fide allosteric inhibitors of integrase function. Furthermore, we show that 2-(quinolin-3-yl) acetic acid derivatives block the formation of the stable synaptic complex between integrase and viral DNA by allosterically stabilizing an inactive multimeric form of integrase. In addition, these compounds inhibit LEDGF binding to the stable synaptic complex. This multimode mechanism of action concordantly results in cooperative inhibition of the concerted integration of viral DNA ends in vitro and HIV-1 replication in cell culture. Our findings, coupled with the fact that high cooperativity of antiviral inhibitors correlates with their increased instantaneous inhibitory potential, an important clinical parameter, argue strongly that improved 2-(quinolin-3-yl) acetic acid derivatives could exhibit desirable clinical properties.

[1]  Robert Craigie,et al.  Retroviral DNA integration: reaction pathway and critical intermediates , 2006, The EMBO journal.

[2]  Myriam Witvrouw,et al.  Discovery of a small-molecule HIV-1 integrase inhibitor-binding site. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[3]  P. Cherepanov.  LEDGF/p75 interacts with divergent lentiviral integrases and modulates their enzymatic activity in vitro , 2006, Nucleic acids research.

[4]  S. A. Chow,et al.  A new functional role of HIV-1 integrase during uncoating of the viral core , 2010, Immunologic research.

[5]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[6]  Lin Shen,et al.  Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs , 2008, Nature Medicine.

[7]  A. Engelman.  Pleiotropic Nature of HIV‐1 Integrase Mutations , 2011 .

[8]  A. Engelman,et al.  A tripartite DNA-binding element, comprised of the nuclear localization signal and two AT-hook motifs, mediates the association of LEDGF/p75 with chromatin in vivo , 2006, Nucleic acids research.

[9]  A. Engelman,et al.  Correlation of Recombinant Integrase Activity and Functional Preintegration Complex Formation during Acute Infection by Replication-Defective Integrase Mutant Human Immunodeficiency Virus , 2012, Journal of Virology.

[10]  A. Engelman,et al.  Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. , 1994, Science.

[11]  A. Marchand,et al.  Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. , 2010, Nature chemical biology.

[12]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[13]  Rolf Boelens,et al.  The DNA-binding domain of HIV-1 integrase has an SH3-like fold , 1995, Nature Structural Biology.

[14]  Jay Painter,et al.  Electronic Reprint Biological Crystallography Optimal Description of a Protein Structure in Terms of Multiple Groups Undergoing Tls Motion Biological Crystallography Optimal Description of a Protein Structure in Terms of Multiple Groups Undergoing Tls Motion , 2005 .

[15]  M. Kvaratskhelia,et al.  An Allosteric Mechanism for Inhibiting HIV-1 Integrase with a Small Molecule , 2009, Molecular Pharmacology.

[16]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[17]  A. Engelman,et al.  Structure-based modeling of the functional HIV-1 intasome and its inhibition , 2010, Proceedings of the National Academy of Sciences.

[18]  P. Brown,et al.  Monoclonal antibodies against human immunodeficiency virus type 1 integrase: epitope mapping and differential effects on integrase activities in vitro , 1996, Journal of virology.

[19]  Krishan K. Pandey,et al.  Transcriptional Coactivator LEDGF/p75 Modulates Human Immunodeficiency Virus Type 1 Integrase-Mediated Concerted Integration , 2007, Journal of Virology.

[20]  A. Gronenborn,et al.  Solution structure of the N-terminal zinc binding domain of HIV-1 integrase , 1997, Nature Structural Biology.

[21]  K. Musier-Forsyth,et al.  FRET analysis reveals distinct conformations of IN tetramers in the presence of viral DNA or LEDGF/p75 , 2011, Nucleic acids research.

[22]  Luba Tchertanov,et al.  Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro , 2008, Antimicrobial Agents and Chemotherapy.

[23]  A. Engelman,et al.  A Novel Co-Crystal Structure Affords the Design of Gain-of-Function Lentiviral Integrase Mutants in the Presence of Modified PSIP1/LEDGF/p75 , 2009, PLoS pathogens.

[24]  A. Engelman,et al.  Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  D. Hazuda,et al.  Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase , 2007, AIDS.

[26]  F. Bushman,et al.  Identification of a small-molecule binding site at the dimer interface of the HIV integrase catalytic domain. , 2001, Acta crystallographica. Section D, Biological crystallography.

[27]  D. Moras,et al.  Structural basis for HIV‐1 DNA integration in the human genome, role of the LEDGF/P75 cofactor , 2009, The EMBO journal.

[28]  E. De Clercq,et al.  LEDGF/p75 Is Essential for Nuclear and Chromosomal Targeting of HIV-1 Integrase in Human Cells* , 2003, Journal of Biological Chemistry.

[29]  Kerim Babaoglu,et al.  Affinities between the Binding Partners of the HIV-1 Integrase Dimer-Lens Epithelium-derived Growth Factor (IN Dimer-LEDGF) Complex , 2009, The Journal of Biological Chemistry.

[30]  J. Nettleship,et al.  Methods for protein characterization by mass spectrometry, thermal shift (ThermoFluor) assay, and multiangle or static light scattering. , 2008, Methods in molecular biology.

[31]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[32]  Y. Pommier,et al.  HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trial. , 2004, Current topics in medicinal chemistry.

[33]  Pamela A. Silver,et al.  Identification of an Evolutionarily Conserved Domain in Human Lens Epithelium-derived Growth Factor/Transcriptional Co-activator p75 (LEDGF/p75) That Binds HIV-1 Integrase* , 2004, Journal of Biological Chemistry.

[34]  A. Engelman,et al.  Dynamic Modulation of HIV-1 Integrase Structure and Function by Cellular Lens Epithelium-derived Growth Factor (LEDGF) Protein* , 2008, Journal of Biological Chemistry.

[35]  A. Engelman,et al.  Retroviral intasome assembly and inhibition of DNA strand transfer , 2010, Nature.

[36]  Joseph Rosenbluh,et al.  Inhibiting HIV-1 integrase by shifting its oligomerization equilibrium , 2007, Proceedings of the National Academy of Sciences.

[37]  R. Siliciano,et al.  A novel method for determining the inhibitory potential of anti-HIV drugs. , 2009, Trends in pharmacological sciences.